60 DEGREES PHARMACEUTICALS LLC (SXTP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.92-1.16%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SXTP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -84.4% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 19.1% |
Growth built into the price is above our model estimate.
The price assumes 103.5 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name is a smaller-cap name (higher miss base rate) and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SXTP — private placement
Dated 2026-08-04
Entry into a Material Definitive Agreement On July 30, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell in a private placement offering (the “Private Placement”) an aggregate of (i) 191,571 shares of its common stock, par value $0.0001 per share (the “Common Stock”) at a purchase price of $1.74 per share a…
Why it matters: More revenue from ARAKODA matters. It helps the company become profitable by 2028.
Supportive ifQuarterly revenue from ARAKODA grows by more than 15% year over year.
Worry ifQuarterly revenue from ARAKODA declines or grows less than 5% year over year.
Why it matters: More directors could help governance and boost investor trust.
Supportive ifA new director has been added to the Board.
Worry ifNo new directors or governance changes have been announced.
Why it matters: The results will indicate if tafenoquine can expand its use beyond malaria. This could drive future revenue.
Supportive ifThe tafenoquine trial for babesiosis has good early results. It shows it works and is safe.
Worry ifThe tafenoquine trial for babesiosis has bad early results. It may not work or be safe.
Why it matters: This will bring in $1 million for operations and working capital.
Supportive ifThe private placement will close on or before July 31, 2026.
Worry ifThe private placement fails to close due to unmet conditions.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$211 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $1,213 loss on $10,000 · 12.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,723 loss on $10,000 · 87.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The results will show progress towards the NDA submission for babesiosis.
Watch forThe analysis shows good results. This is a positive sign for development.
Also watch forThe analysis shows bad results. This stops further development.
Why it matters: Earnings results will show how the company is doing financially.
Watch forThe earnings report shows more revenue or fewer losses than before.
Also watch forThe earnings report shows ongoing losses or falling revenue.
Why it matters: Getting funding will help the company run better. It may also improve finances.
Supportive ifThe private placement closes successfully and the funds come in as expected.
Worry ifThe private placement fails to close or raises significantly less than $1 million.
Why it matters: This submission is key for growing the product's market and revenue.
Supportive ifThe company files the NDA for tafenoquine earlier than planned.
Worry ifThe company delays the NDA submission beyond Q1 2028.
Why it matters: Revenue trends will show if the company is on track for profits by 2028.
Watch forQ3 revenue shows growth compared to the previous quarter.
Also watch forQ3 revenue falls again compared to the last quarter.